ArticleFrontiers in cardiovascular medicine2026
Prognostic value of the systemic immune-inflammation index in acute limb ischemia undergoing endovascular therapy.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acute limb ischemia (ALI) is a vascular emergency associated with major amputation and mortality, highlighting the need for early risk stratification. The systemic immune-inflammation index (SII), calculated from platelet, neutrophil, and lymphocyte counts, is a composite biomarker reflecting systemic inflammation and immune status. Although SII has demonstrated prognostic value in various cardiovascular diseases, its role in patients with ALI undergoing endovascular therapy remains unclear. Objective: To evaluate the association between baseline SII and 12-month outcomes in patients with ALI undergoing endovascular therapy. Methods: This retrospective, single-center cohort study included 47 consecutive patients with ALI treated with endovascular therapy. Patients were dichotomized at the median baseline SII into high and low SII groups. The primary outcome was a composite of major amputation or all-cause mortality within 12 months. Kaplan-Meier survival analysis and multivariable Cox proportional hazards regression models were performed to assess associations between baseline SII and outcomes, adjusting for age, sex, severe ischemia (Rutherford IIb-III), and renal function (eGFR). Receiver operating characteristic analysis evaluated the discriminatory ability of SII. Results: The primary outcome occurred in 20 patients (42.6%) and was more frequent in the high-SII group than in the low-SII group (62.5% vs. 21.7%, Conclusion: In this exploratory cohort study, elevated baseline SII was associated with a higher risk of the composite outcome of major amputation or all-cause mortality within 12 months in patients with ALI undergoing endovascular therapy. This association appeared to reflect overall adverse prognosis, whereas its specific association with major amputation remains uncertain. These findings, including the ROC-based analyses, should be considered hypothesis-generating and require validation in larger prospective multicenter studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.